EnteroMedics Inc.(ETRM): For the most recent quarter end, EnteroMedics Inc. reported Annual Earnings of $-11.89. Based on the filings, last years Annual Earnings was, $-298.6. For the most recent quarter end, ETRM reported a surprise Earnings per Share of 66% . The consensus estimate for current quarter is $-34.97 and for the current fiscal year, the estimate is $-169.93. For the Next fiscal year, the estimate is $-125.87 based on the consensus. St. Paul based EnteroMedics Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Feb 22, 2017.
EnteroMedics Inc. has received $-34.97 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 1 Financial Advisor in the Stock Trading Firms. The EPS growth rate is projected at 47.37%. EnteroMedics Inc. reported better than expected with a surprise EPS of 66% or $23.08 during its most recent quarterly earnings. The Actual EPS was $-11.89 compared to the Estimated EPS of $-34.97. According to the corporate earnings calendar, EnteroMedics Inc. will release next earnings on Feb 22, 2017 with an estimated EPS consensus of $-34.97. Based on the consensus of stock financial advisors the stock has a price target of $139.86. Current year estimate on EPS consensus is $-169.93.
For Dividend Investing Stock Market Traders EnteroMedics Inc. has a Dividend Yield of 0% with an Annual Dividend of $0.
Company has reported several Insider transactions to the SEC, on Jun 6, 2016, Peter M. Delange (SVP, Ops & Bus Dev) purchased 20,000 shares at 0.55 per share price.On May 18, 2016, Dan W Gladney (CEO) purchased 84,745 shares at 0.72 per share price.On Nov 16, 2015, Mark B Knudson (CEO) purchased 310,000 shares at 0.16 per share price.
EnteroMedics Inc. (NASDAQ:ETRM) witnessed a decline in the market cap on Wednesday as its shares dropped 3.61% or 0.24 points. After the session commenced at $6.6, the stock reached the higher end at $6.76 while it hit a low of $6.1738. With the volume soaring to 1,154,696 shares, the last trade was called at $6.4. The company has a 52-week high of $88.548229. The company has a market cap of $25 million and there are 3,954,728 shares in outstanding. The 52-week low of the share price is $1.75.
EnteroMedics Inc. was established to develop and commercialize a new therapeutic platform for treating a wide range of acute and chronic diseases that are mediated by the vagal nerves. Due to the large unmet need for more effective surgical management of obesity, and following an in-depth analysis of how the vagus nerve affects food intake and processing, EnteroMedics has selected obesity management as its primary focus.